AAD 2020: Lebrikizumab treatment for aspecific dermatitis, significant improvement in the quality of life of patients

Lilly and its wholly-owned subsidiary Dermira announced that they will present the latest data on the trial of lebrikizumab's phase IIb clinical trial for moderate to severe aditial dermatitis at the 2020 Virtual Meeting of the American Society of Dermatology (AAD)This study shows that Lebrikizumab can provide rapid and clinically meaningful improvements in patients' itching, sleep and quality of lifeProfessor Clara Kest, Director of the Department of Dermatological Dermatism at The Icahn School of Medicine at Mount Sinai, said: "Understanding the potential of lebrikizumab to improve skin symptoms and other common symptoms in patients with teriotmatitis, such as itching and lack of sleep, is critical to understanding the true potential of lebrikizumabThese results suggest that lebrikizumab can significantly improve the symptoms of the most troubled patients."Aditaphilive dermatitis is a chronic, itchy, inflammatory skin disease that most often affects children, but also affects many adultsClinical features of adhesion dermatitis include dry skin, erythema, oozing and knotting, as well as moss-like changes